138 related articles for article (PubMed ID: 10325501)
21. Improved oral delivery of N-(4-hydroxyphenyl)retinamide with a novel LYM-X-SORB organized lipid complex.
Maurer BJ; Kalous O; Yesair DW; Wu X; Janeba J; Maldonado V; Khankaldyyan V; Frgala T; Sun BC; McKee RT; Burgess SW; Shaw WA; Reynolds CP
Clin Cancer Res; 2007 May; 13(10):3079-86. PubMed ID: 17505011
[TBL] [Abstract][Full Text] [Related]
22. Effects of N-(4-hydroxyphenyl)retinamide on hTERT expression in the bronchial epithelium of cigarette smokers.
Soria JC; Moon C; Wang L; Hittelman WN; Jang SJ; Sun SY; Lee JJ; Liu D; Kurie JM; Morice RC; Lee JS; Hong WK; Mao L
J Natl Cancer Inst; 2001 Aug; 93(16):1257-63. PubMed ID: 11504771
[TBL] [Abstract][Full Text] [Related]
23. Relationship between systematic biopsies and histological features of 222 radical prostatectomy specimens: lack of prediction of tumor significance for men with nonpalpable prostate cancer.
Noguchi M; Stamey TA; McNeal JE; Yemoto CM
J Urol; 2001 Jul; 166(1):104-9; discussion 109-10. PubMed ID: 11435833
[TBL] [Abstract][Full Text] [Related]
24. Fenretinide: induction of apoptosis and endogenous transforming growth factor beta in PC-3 prostate cancer cells.
Roberson KM; Penland SN; Padilla GM; Selvan RS; Kim CS; Fine RL; Robertson CN
Cell Growth Differ; 1997 Jan; 8(1):101-11. PubMed ID: 8993839
[TBL] [Abstract][Full Text] [Related]
25. Testosterone replacement therapy in hypogonadal men at high risk for prostate cancer: results of 1 year of treatment in men with prostatic intraepithelial neoplasia.
Rhoden EL; Morgentaler A
J Urol; 2003 Dec; 170(6 Pt 1):2348-51. PubMed ID: 14634413
[TBL] [Abstract][Full Text] [Related]
26. Minute focus of prostate cancer on needle biopsy: correlation with radical prostatectomy specimen.
Montanari E; Del Nero A; Gazzano G; Mangiarotti B; Bernardini P; Longo F; Cordima G; Itri E
Arch Ital Urol Androl; 2009 Mar; 81(1):9-12. PubMed ID: 19499751
[TBL] [Abstract][Full Text] [Related]
27. Pathological features of prostate cancer detected on initial and repeat prostate biopsy: results of the prospective European Prostate Cancer Detection study.
Djavan B; Mazal P; Zlotta A; Wammack R; Ravery V; Remzi M; Susani M; Borkowski A; Hruby S; Boccon-Gibod L; Schulman CC; Marberger M
Prostate; 2001 May; 47(2):111-7. PubMed ID: 11340633
[TBL] [Abstract][Full Text] [Related]
28. Results of rebiopsy for suspected prostate cancer in symptomatic men with elevated PSA levels.
Perachino M; di Ciolo L; Barbetti V; Ardoino S; Vitali A; Introini C; Vigliercio G; Puppo P
Eur Urol; 1997; 32(2):155-9. PubMed ID: 9286645
[TBL] [Abstract][Full Text] [Related]
29. Prostate cancer diagnosis using a saturation needle biopsy technique after previous negative sextant biopsies.
Stewart CS; Leibovich BC; Weaver AL; Lieber MM
J Urol; 2001 Jul; 166(1):86-91; discussion 91-2. PubMed ID: 11435830
[TBL] [Abstract][Full Text] [Related]
30. Prostatic intraepithelial neoplasia and endocrine manipulation.
van der Kwast TH; Labrie F; Têtu B
Eur Urol; 1999; 35(5-6):508-10. PubMed ID: 10325515
[TBL] [Abstract][Full Text] [Related]
31. Oral fenretinide in biochemically recurrent prostate cancer: a California cancer consortium phase II trial.
Cheung E; Pinski J; Dorff T; Groshen S; Quinn DI; Reynolds CP; Maurer BJ; Lara PN; Tsao-Wei DD; Twardowski P; Chatta G; McNamara M; Gandara DR
Clin Genitourin Cancer; 2009 Jan; 7(1):43-50. PubMed ID: 19213668
[TBL] [Abstract][Full Text] [Related]
32. Is low-grade prostatic intraepithelial neoplasia a risk factor for cancer?
Goeman L; Joniau S; Ponette D; Van der Aa F; Roskams T; Oyen R; Van Poppel H
Prostate Cancer Prostatic Dis; 2003; 6(4):305-10. PubMed ID: 14663472
[TBL] [Abstract][Full Text] [Related]
33. Prostate health index and prostate cancer gene 3 score but not percent-free Prostate Specific Antigen have a predictive role in differentiating histological prostatitis from PCa and other nonneoplastic lesions (BPH and HG-PIN) at repeat biopsy.
De Luca S; Passera R; Fiori C; Bollito E; Cappia S; Mario Scarpa R; Sottile A; Franco Randone D; Porpiglia F
Urol Oncol; 2015 Oct; 33(10):424.e17-23. PubMed ID: 26162485
[TBL] [Abstract][Full Text] [Related]
34. IGFBP2 as an immunohistochemical marker for prostatic adenocarcinoma.
Ambrosini-Spaltro A; Farnedi A; Montironi R; Foschini MP
Appl Immunohistochem Mol Morphol; 2011 Jul; 19(4):318-28. PubMed ID: 21304397
[TBL] [Abstract][Full Text] [Related]
35. MR imaging evaluation with a transrectal surface coil of local recurrence of prostatic cancer in men who have undergone radical prostatectomy.
Silverman JM; Krebs TL
AJR Am J Roentgenol; 1997 Feb; 168(2):379-85. PubMed ID: 9016212
[TBL] [Abstract][Full Text] [Related]
36. Androgen receptor expression in prostatic intraepithelial neoplasia and cancer.
Sweat SD; Pacelli A; Bergstralh EJ; Slezak JM; Bostwick DG
J Urol; 1999 Apr; 161(4):1229-32. PubMed ID: 10081875
[TBL] [Abstract][Full Text] [Related]
37. Mesonephric remnant hyperplasia involving prostate and periprostatic tissue: findings at radical prostatectomy.
Chen YB; Fine SW; Epstein JI
Am J Surg Pathol; 2011 Jul; 35(7):1054-61. PubMed ID: 21606823
[TBL] [Abstract][Full Text] [Related]
38. Diagnostic effect of an improved preembedding method of prostate needle biopsy specimens.
Rogatsch H; Moser P; Volgger H; Horninger W; Bartsch G; Mikuz G; Mairinger T
Hum Pathol; 2000 Sep; 31(9):1102-7. PubMed ID: 11014578
[TBL] [Abstract][Full Text] [Related]
39. Regression of mouse prostatic intraepithelial neoplasia by nonsteroidal anti-inflammatory drugs in the transgenic adenocarcinoma mouse prostate model.
Narayanan BA; Narayanan NK; Pittman B; Reddy BS
Clin Cancer Res; 2004 Nov; 10(22):7727-37. PubMed ID: 15570007
[TBL] [Abstract][Full Text] [Related]
40. Expression of ERG protein, a prostate cancer specific marker, in high grade prostatic intraepithelial neoplasia (HGPIN): lack of utility to stratify cancer risks associated with HGPIN.
He H; Osunkoya AO; Carver P; Falzarano S; Klein E; Magi-Galluzzi C; Zhou M
BJU Int; 2012 Dec; 110(11 Pt B):E751-5. PubMed ID: 23046279
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
